AN2 Therapeutics IPO Presentation Deck
March 2022, 27 slides
  1. AN2 Therapeutics
  2. Related Decks
  3. IPO Presentation Decks
an therapeutics developing treatments for rare chronic and serious infectious diseases with high unmet needs | AN2 Therapeutics
disclaimer an therapeutics | AN2 Therapeutics
offering summary an therapeutics | AN2 Therapeutics
preside it an | AN2 Therapeutics
team with significant experience in bringing medicines to market adjuvant capital sol an therapeutics surveyor | AN2 Therapeutics
an therapeutics is a clinical stage pivotal phase ready antibiotic product candidate for non tuberculous lung disease company developing treatments for rare chronic and serious infectious diseases with high unmet needs large market opportunity given the high unmet need the only approved therapy for lung disease had net sales of in its third year on the market ideal target product profile novel mechanism of action broad spectrum activity convenient once daily oral dosing superior profile compared to soc combination regimen in preclinical models multiple phase studies out to days of dosing support well tolerated dose and high probability of target attainment phase pivotal trial expected to support regulatory approval for treatment refractory mac lung disease plan to enroll first patient topline phase data mid alignment with on phase trial design and accepted fast track and orphan drug designations granted potential to develop to address additional geographies and indications we expect our boron chemistry to drive future pipeline of differentiated compounds an therapeutics | AN2 Therapeutics
continuing pioneering anti infective work originating from highly productive boron chemistry platform an therapeutics launched in an in licensed from acquired by in an raised to fund development of launched for an therapeutics | AN2 Therapeutics
pipeline targets high unmet needs in rare chronic and serious infectious diseases lung disease boron chemistry approach enables targeting of novel biological targets mid phase topline data japan attest as an therapeutics | AN2 Therapeutics
lung disease an therapeutics | AN2 Therapeutics
lung disease a rare chronic and progressive infectious disease is a group of species of commonly found in water and soil unlike tuberculosis not transmitted person to person is being developed for the most common type of complex mac mac causes of cases of lung disease this complex currently includes species most common are and chimaera symptoms similar to those associated with other chronic respiratory diseases cough sputum production fatigue causes chronic infection that progresses to fibrosis permanent lung damage and respiratory failure women and age group most affected year mortality rate between an therapeutics | AN2 Therapeutics
lung disease and growing market opportunity initial indication targeting treatment refractory mac lung disease estimated patients with lung disease in | AN2 Therapeutics
current treatment regimens for patients with complex mac lung disease leave a significant unmet medical need at a if culture positive after months of treatment all treatments except are used off label treatment refractory patients an therapeutics | AN2 Therapeutics
inhaled first and only approved lung disease drug is associated with a high discontinuation rate and increased adverse events versus soc therapy alone pivotal study convert results convert study parameter control efficacy culture converted by month safety withdrawn from study upper respiratory adverse events boxed warnings associated with an increased risk of respiratory conditions hypersensitivity pneumonitis bronchospasm exacerbation of underlying lung disease and hemoptysis that have led to hospitalizations in some cases other common side effects dysphonia cough upper airway irritation pain fatigue diarrhea and nausea an therapeutics | AN2 Therapeutics
novel mechanism of action inhibits the protein synthesis enzyme leucyl by binding to the terminal adenosine ribose of in the editing site leucine in site poet an therapeutics | AN2 Therapeutics
broad activity in activity against clinical isolates of mac with between to range activity of and against isolates of mac including isolates isolates complex is a generic used to treat patients with mac lung disease and is the only currently approved therapy for the treatment of mac lung disease an therapeutics | AN2 Therapeutics
antibacterial activity in a chronic model of mac lung disease in showed improved antibacterial activity of at all doses compared to the daily humanized dose of lung disease in mice against an therapeutics | AN2 Therapeutics
antibacterial activity in a chronic model of mac lung disease in mice significant reductions in mac with superior decreases with soc regimen compared to soc alone an therapeutics | AN2 Therapeutics
a day phase dose ranging study of oral supports once daily dose for patients with treatment refractory mac lung disease phase design and results mere male placebo generally well tolerated no serious adverse events no severe aes no deaths linear and predictable results support further clinical development of in lung disease data from and other clinical studies combined into population model results used in combination with preclinical data to determine oral dosage for study phase pivotal trial once daily dose achieved high probability of target attainment for treatment of mac lung disease and was well tolerated an therapeutics | AN2 Therapeutics
favorable trial results from phase showed the concentration in lung macrophages site of infection was higher than in plasma am results suggest therapeutically relevant doses of may be achieved in macrophages at doses that are substantially lower than in previous trials an therapeutics | AN2 Therapeutics
phase part a phase pivotal clinical in treatment refractory mac lung disease not i laced confirmed anticipated trial design during meeting with activities underway phase part seamless enrollment | AN2 Therapeutics
commercial strategy establish treatment refractory market significant growth opportunity in us markets with additional labeled indications japan an therapeutics | AN2 Therapeutics
attractive target product profile to address unmet needs in with potential to become an important component of therapy planned target product profile criteria targeted for treatment refractory patients broad spectrum against isolates novel target with no observed potential for improved safety tolerability for long duration potential for predictable at site of infection potential for reducing als an therapeutics | AN2 Therapeutics
intellectual property up to years of exclusivity united states japan composition of matter patent expires june without hatch waxman extensions pediatric exclusivity up to years of extensions protection up to june regulatory exclusivity up to years post marketing orphan drug years gain act years patents issued in provides years of exclusivity from launch with as similar mechanisms available in japan an therapeutics | AN2 Therapeutics
existing cash funds value driving milestones series a closed series closed march cash as of existing cash plus proceeds from provides expected capital to support operations for at least months phase topline data topline data adjuvant res of the a | AN2 Therapeutics
our global health commitment an therapeutics an leadership team is committed to applying our know how to help solve some of the infections in global health intent is from sources such as public and private agencies and foundations to fund these efforts primarily through non dilutive funding the highest priority research with is currently conducting preclinical university global health an therapeutics i | AN2 Therapeutics
an therapeutics is a clinical stage pivotal phase ready antibiotic product candidate for non tuberculous lung disease company developing treatments for rare chronic and serious infectious diseases with high unmet needs large market opportunity given the high unmet need the only approved therapy for lung disease had net sales of in its third year on the market ideal target product profile novel mechanism of action broad spectrum activity convenient once daily oral dosing superior profile compared to soc combination regimen in preclinical models multiple phase studies out to days of dosing support well tolerated dose and high probability of target attainment phase pivotal trial expected to support regulatory approval for treatment refractory mac lung disease plan to enroll first patient topline phase data mid alignment with on phase trial design and accepted fast track and orphan drug designations granted potential to develop to address additional geographies and indications we expect our boron chemistry to drive future pipeline of differentiated compounds an therapeutics | AN2 Therapeutics
an therapeutics developing treatments for rare chronic and serious infectious diseases with high unmet needs | AN2 Therapeutics
See More
AN2 Therapeutics
IPO Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Lung
Recent decks by AN2 Therapeutics
Investor Presentation
March 2025
Investor Presentation
February 2025
Investor Presentation
August 2022
See all presentations by AN2 Therapeutics (4 decks)
Related decks
Genprex
Investor Presentation
October 2022
Genelux
Investor Presentation
December 2023
Genelux
Investor Presentation
February 2024
AstraZeneca
Investor Event
September 2024
Genelux
Investor Presentation
July 2023
AstraZeneca
Investor Event
June 2023
Genelux
Investor Presentation
October 2023
Genprex
Investor Presentation
November 2024
Recent decks by AN2 Therapeutics
See all presentations (4 decks)
Investor Presentation
March 2025
Investor Presentation
February 2025
Investor Presentation
August 2022
Genprex
Investor Presentation
October 2022
Genelux
Investor Presentation
December 2023
Genelux
Investor Presentation
February 2024
AstraZeneca
Investor Event
September 2024
Genelux
Investor Presentation
July 2023
AstraZeneca
Investor Event
June 2023
Genelux
Investor Presentation
October 2023
Genprex
Investor Presentation
November 2024
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io